Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy Kevin Kunzmann

Published Date: 21 Nov 2025

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot